Information Provided By: 
Fly News Breaks for April 28, 2016
DVAX
Apr 28, 2016 | 07:06 EDT
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
